Developing bioengineered organs for life-threatening conditions

Leadership Team


Jim McGorry - President and Chief Executive Officer –most recently served as Executive Vice President and General Manager, Translational Oncology Solutions for Champions Oncology and previously was Executive Vice President of Commercial Operations at Accellent. During his 12-year tenure at Genzyme, he held leadership positions across several therapeutic areas, including Bio Surgery, Cardiac Surgery, Oncology and Transplant. Mr. McGorry also was President of Clineffect Systems, an electronic medical records company. He began his life sciences career with Baxter Healthcare Corporation, where he spent 11 years in positions of increasing responsibility. Mr. McGorry also served as an officer in the United States Army for six years, including commanding a special operations Green Beret SCUBA detachment. He has more than 25 years of experience as a life science business leader in biologics, personalized medicine and medical devices, including multiple product launches. He also has been a member of the HART Board of Directors since February 2013. Mr. McGorry has an MBA with a concentration in healthcare from Duke University, Fuqua School of Business, and a B.S. in engineering from the United States Military Academy at West Point where he was the president of his class.


Tom McNaughton - serves as our Chief Financial Officer. Mr. McNaughton was the Chief Financial Officer of Harvard Bioscience since November 2008. From 2007 to 2008, Mr. McNaughton was a consultant providing services primarily to an angel-investing group and a silicon manufacturing start-up. From 2005 to 2007, Mr. McNaughton served as Vice President of Finance and Chief Financial Officer for Tivoli Audio, LLC, a venture capital-backed global manufacturer of premium audio systems. Prior to joining Tivoli Audio, LLC, from 1990 to 2005, Mr. McNaughton served in various managerial positions in the areas of financial reporting, treasury, investor relations, and acquisitions within Cabot Corporation, a global manufacturer of fine particulate products, and served from 2002 to 2005 as Finance Director, Chief Financial Officer of Cabot Supermetals, a $350 million Cabot division that provides high purity tantalum and niobium products to the electronics and semiconductor industries. Mr. McNaughton practiced from 1982 to 1990 as a Certified Public Accountant in the audit services group of Deloitte & Touche, LLP. Mr. McNaughton holds a B.S. in accounting and finance from Babson College.


Saverio LaFrancesca – Executive Vice President and Chief Medical Officer... Is a cardiothoracic surgeon with extensive clinical experience committed to the clinical translation of transformative medical research. Saverio has a unique combination of experience that features over 25 years of academic clinical surgical practice and innovative research, with a foundation in the cardiovascular, thoracic transplantation, cardiac assist device and regenerative medicine fields. He joins the company from the Dept. of Cardiovascular Surgery and Transplantation at the DeBakey Heart and Vascular Center at the Houston Methodist Hospital, where he developed the current surgical and perfusion techniques for thoracic organ procurement and preservation and where he was also the Director of the Exvivo lung perfusion laboratory. Previously he was an attending surgeon at the Department of Cardiopulmonary Transplantation at the Texas Heart Institute in Houston, Texas. Saverio still holds an appointment as Associate Professor of Surgery at the University of Rome "La Sapienza” in Rome, Italy. He received his M.D. in medicine and surgery in 1985 at the University of Palermo. Saverio did his Residency in Cardiovascular Surgery in the Dept. of Cardiovascular Surgery at the University of Rome "La Sapienza". He then completed his post-doctoral training with fellowships at the Texas Heart Institute under the supervision of pioneer surgeon Denton Cooley. He was also a Clinical/ Research fellow at McGill University in Montréal, Québec, Canada and at the Baylor College of Medicine in Houston. Saverio holds UNOS certifications as heart transplant surgeon and lung transplant surgeon. He is also certified as surgeon for the use of the HeartMate and the Jarvik 2000 left ventricular assist devices.


Al Correia – Vice President of Sales & Manufacturing……Previously as Vice President of Operations at Cambridge Biomedical, he was involved in all aspects of the company including Sales, Marketing, development and the laboratory where he designed and built the new laboratory facility. As Vice President of Marketing at VelQuest Corp, a provider of GMP compliance software to the pharmaceutical industry. He has presented over 50 workshops and seminars at international conferences and meetings on various compliance topics including electronic record requirements, data acquisition and Part 11. As Vice President and General Manager at Unisyn Technologies, a contract manufacturer of Pre-clinical, Phase 1 and Phase 2 therapeutics, he designed built and ran a GMP production plant. A major project completed while head of development was to design a new line of bioreactors. Prior to Unisyn, Al held several technical and marketing management positions at Zymark Corporation and was a cofounder of Xydex, a sample handling company that was acquired by Genex. He also held positions in the sales and application laboratory at Waters Associates. Al received a degree in Chemistry from the College of the Holy Cross.


Thomas Bollenbach, Ph.D. – Vice President of Research and Development joined the company from Organogensis where he Implemented and completed efficacy and preclinical pharmacology and toxicology programs for bioengineered living skin graft in anticipation of an IND. His group developed wound healing, skin grafting, and oral regeneration models in swine which was unique in the industry for the in vivo evaluation of adult stem cell suspensions, living, bioengineered constructs and biomaterials. His ability to maintain strong cross-functional interactions with Clinical Operations ensured meaningful translation of swine studies while partnering with business units to provide scientific support to corporate strategies. Previously he was at the Boyce Thompson Institute of Cornell University where he developed expertise in molecular cloning, analysis of tissue and cells for DNA and RNA by qualitative and quantitative methods, in vitro characterization of RNA structure, in vitro translation assays, ribonuclease assays, protein-RNA interactions Tom received his BSc in biochemistry from the University of Waterloo and his Ph.D. in biochemistry from the University of Notre Dame.